![\"\"](\"http:\/\/www.sinotau.com\/wp-content\/uploads\/2023\/10\/640-3.png\")
<\/figure><\/div>\n\n\u00a0<\/p>\n
Current methods for early diagnosis of AD include A\u03b2 testing by obtaining\u00a0cerebrospinal fluid\u00a0through\u00a0lumbar puncture\u00a0and A\u03b2 testing by positron emission computed tomography (PET). Lumbar puncture iore difficult for paties an invasive test, which is mnts and families to accept, while PET is not only non-invasive, but also the most accurate.<\/p>\n
A\u03b2 detection by PET requires\u00a0intravenous injection\u00a0of A\u03b2 imaging agent, but there is no A\u03b2 imaging agent that can be widely used in clinical application in China. In order to fill this clinical gap and meet the needs of AD patients, Sinotau has\u00a0conducted\u00a0the R&D of A\u03b2-PET imaging agent – florbetaben F18, and has\u00a0submitted\u00a0a new drug application (NDA), which is the only A\u03b2-PET imaging agent that has submitted an NDA. It is expected that florbetaben F18 will be widely used in the clinic next year.<\/p>\n
Florbetaben F18 is an A\u03b2-PET imaging agent used in brain scans of patients with cognitive memory problems, so that doctors can see if they have large amounts of beta-amyloid plaques in their brains. This product has been marketed in Europe and America, and will be the first A\u03b2-PET imaging agent that can be applied to AD diagnosis in China. It\u00a0can be used not only\u00a0for the early diagnosis of AD,\u00a0but also\u00a0has been widely used abroad for patients screening and\u00a0efficacy assessment\u00a0in clinical trials of\u00a0AD therapeutics.<\/p>\n
The future clinical application of these AD therapeutics\u00a0will not be\u00a0possible without the accurate diagnosis of A\u03b2-PET imaging agents. The close\u00a0collaboration\u00a0between\u00a0precision\u00a0diagnosis and effective\u00a0therapy\u00a0will provide a comprehensive solution to the challenge of early diagnosis and reversal of AD.<\/p>\n
\u00a0<\/p>\n\n
![\"\"](\"http:\/\/www.sinotau.com\/wp-content\/uploads\/2023\/10\/640-1-1.png\")
<\/figure><\/div>\n\n\u00a0<\/p>\n
Amyloid PET imaging scans from a representative participant in the Phase II clinical trial of Lecanemab<\/em> \u00a0<\/p>\n About\u00a0Sinotau Pharmaceutical\u00a0Group<\/strong> On September 28, Beijing time, Biogen and Eisai, foreign companies\u00a0dedicated to\u00a0the R&D of Alzheimer’s disease (AD) drugs, announced that its new AD drug Lecanemab Phase III clinical trial met its\u00a0primary endpoint,\u00a0which means that the drug can\u00a0effectively\u00a0improve patients’\u00a0cognitive ability\u00a0and slow down the\u00a0progression\u00a0of AD. Lecanemab is the first beta-amyloid (A\u03b2) antibody to achieve positive results in a\u00a0confirmatory\u00a0Phase […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[11],"tags":[],"class_list":["post-3816","post","type-post","status-publish","format-standard","hentry","category-company-news"],"meta_box":[],"_links":{"self":[{"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/posts\/3816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/comments?post=3816"}],"version-history":[{"count":6,"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/posts\/3816\/revisions"}],"predecessor-version":[{"id":3824,"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/posts\/3816\/revisions\/3824"}],"wp:attachment":[{"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/media?parent=3816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/categories?post=3816"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/tags?post=3816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
The image on the left is taken before the participant has started on the investigational treatment. The image on the right is taken after 18 months of\u00a0investigational\u00a0treatment with\u00a0Lecanemab.\u00a0A\u03b2-PET imaging can accurately, qualitatively and quantitatively measure the level of amyloid plaques in the brain. PET qualitative readings showed a significant reduction of amyloid plaque burden in the brain compared to the\u00a0pre-treatment period,\u00a0and PET quantitative analysis showed\u00a00.306(22%) reduction in SUVR after treatment.<\/em>
(image resource:\u00a0https:\/\/www.aheadstudy.org\/participation-requirements\/)<\/em><\/p>\n
Sinotau Pharmaceutical\u00a0Group\u00a0officially launched the R&D of new generation radiopharmaceuticals in 2014.\u00a0Sinotau,\u00a0headquartered in Beijing,\u00a0has\u00a0modern radiopharmaceutical smart production bases in Jiangsu, Guangdong and Sichuan, and a branch office in the US,\u00a0having formed business cooperation with more than a dozen multinational pharmaceutical companies. Relying on the world’s leading R&D resources of radiopharmaceutical\u00a0precision\u00a0diagnosis and therapy, Sinotau has taken the lead in laying\u00a0out a number of\u00a0targeted therapeutic and precision diagnostic radiopharmaceuticals in the fields of oncology, neurodegenerative diseases and cardiovascular disease, which are in or have completed clinical trials and will be launched in the coming years. Since April 2020,\u00a0Sinotau\u00a0has successfully\u00a0closed\u00a0nearly 1 billion RMB\u00a0and has\u00a0been favored by\u00a0major investment institutions, with plans to land on major capital markets in the near future.<\/p>","protected":false},"excerpt":{"rendered":"